Showing results (151-160 of 275) with videos related to

Sort By:
Pageof 28
The Journal of Hygiene|December 1, 1979
Influenza vaccination with live-attenuated and inactivated virus-vaccines during an outbreak of diseaseG Rocchi, G Ragona, C Piga, et al.
AIDS Research and Human Retroviruses|May 1, 1997
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapyM Andreoni, L Sarmati, L Ercoli, et al.
The Journal of Infectious Diseases|June 1, 1996
In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequenciesH Jacobsen, M Hänggi, M Ott, et al.
Journal of Acquired Immune Deficiency Syndromes|January 1, 1994
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatmentL Sarmati, L Ercoli, S G Parisi, et al.
Journal of Medical Virology|January 4, 1998
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatmentL Sarmati, E Nicastri, G el-Sawaf, et al.
Recenti Progressi in Medicina|April 11, 2001
[Autoantibodies in chronic hepatitis C. Markers of autoimmunity or non-specific events?]F S Vella, P Orlando, F Attanasi, et al.
Annals of Neurology|January 1, 1988
Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological diseaseR Yarchoan, R V Thomas, J Grafman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 1, 1993
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virusC McLaren, M Rozencweig, M Beltangady, et al.
The Biochemical Journal|March 24, 2000
HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductaseD A Davis, F M Newcomb, J Moskovitz, et al.
Antiviral Research|October 1, 1996
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)A Foli, K M Sogocio, B Anderson, et al.
Pageof 28